Zacks: Analysts Expect Urogen Pharma Ltd (URGN) Will Announce Earnings of -$1.08 Per Share

Wall Street brokerages expect Urogen Pharma Ltd (NASDAQ:URGN) to post earnings per share of ($1.08) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Urogen Pharma’s earnings, with the lowest EPS estimate coming in at ($1.14) and the highest estimate coming in at ($1.02). Urogen Pharma posted earnings per share of ($0.02) in the same quarter last year, which would suggest a negative year over year growth rate of 5,300%. The company is scheduled to report its next quarterly earnings report on Tuesday, November 13th.

According to Zacks, analysts expect that Urogen Pharma will report full year earnings of ($4.12) per share for the current financial year, with EPS estimates ranging from ($4.32) to ($3.89). For the next year, analysts anticipate that the firm will report earnings of ($4.93) per share, with EPS estimates ranging from ($6.71) to ($3.47). Zacks’ EPS calculations are an average based on a survey of research firms that that provide coverage for Urogen Pharma.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings results on Tuesday, August 14th. The company reported ($1.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.25). The business had revenue of $0.36 million for the quarter. Urogen Pharma had a negative return on equity of 44.24% and a negative net margin of 470.54%.

A number of research firms have recently weighed in on URGN. Stifel Nicolaus began coverage on Urogen Pharma in a report on Thursday, September 13th. They set a “buy” rating and a $70.00 price target for the company. Oppenheimer set a $75.00 price target on Urogen Pharma and gave the stock a “buy” rating in a report on Tuesday, August 14th. Cowen reiterated a “buy” rating on shares of Urogen Pharma in a report on Tuesday, August 14th. Finally, ValuEngine upgraded Urogen Pharma from a “hold” rating to a “buy” rating in a report on Saturday, June 2nd. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $59.60.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Harel Insurance Investments & Financial Services Ltd. purchased a new position in Urogen Pharma during the 2nd quarter valued at about $129,000. Quantbot Technologies LP purchased a new position in Urogen Pharma during the 1st quarter valued at about $174,000. UBS Group AG boosted its holdings in Urogen Pharma by 31.5% during the 1st quarter. UBS Group AG now owns 3,611 shares of the company’s stock valued at $180,000 after acquiring an additional 865 shares during the period. DAFNA Capital Management LLC purchased a new position in Urogen Pharma during the 1st quarter valued at about $224,000. Finally, Jane Street Group LLC purchased a new position in Urogen Pharma during the 2nd quarter valued at about $227,000. Institutional investors and hedge funds own 71.11% of the company’s stock.

Shares of NASDAQ URGN traded down $0.12 during mid-day trading on Tuesday, reaching $48.90. 30,500 shares of the company’s stock were exchanged, compared to its average volume of 113,268. The stock has a market cap of $681.11 million, a PE ratio of -22.85 and a beta of 2.01. Urogen Pharma has a 52-week low of $25.56 and a 52-week high of $69.57.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.

See Also: Trading Penny Stocks

Get a free copy of the Zacks research report on Urogen Pharma (URGN)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Urogen Pharma (NASDAQ:URGN)

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with's FREE daily email newsletter.

Leave a Reply